These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 16278304

  • 1. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
    Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A, Eder M.
    Blood; 2006 Apr 15; 107(8):3279-87. PubMed ID: 16278304
    [Abstract] [Full Text] [Related]

  • 2. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.
    Chaturvedi A, Battmer K, Schaefer D, Ganser A, Eder M, Scherr M.
    Oligonucleotides; 2007 Apr 15; 17(1):22-34. PubMed ID: 17461760
    [Abstract] [Full Text] [Related]

  • 3. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
    Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ.
    Blood; 2008 Apr 01; 111(7):3821-9. PubMed ID: 18235045
    [Abstract] [Full Text] [Related]

  • 4. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
    Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.
    Blood; 2012 Feb 09; 119(6):1501-10. PubMed ID: 22184410
    [Abstract] [Full Text] [Related]

  • 5. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.
    Blood; 2005 Apr 15; 105(8):3303-11. PubMed ID: 15626746
    [Abstract] [Full Text] [Related]

  • 6. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM.
    Blood; 2012 Mar 08; 119(10):2335-45. PubMed ID: 22262776
    [Abstract] [Full Text] [Related]

  • 7. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
    Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.
    J Natl Cancer Inst; 2013 Mar 20; 105(6):405-23. PubMed ID: 23446755
    [Abstract] [Full Text] [Related]

  • 8. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
    Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI.
    J Biol Chem; 2014 May 30; 289(22):15642-52. PubMed ID: 24753251
    [Abstract] [Full Text] [Related]

  • 9. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK, Rahmani M, Harada H, Dent P, Grant S.
    Blood; 2007 May 01; 109(9):4006-15. PubMed ID: 17218385
    [Abstract] [Full Text] [Related]

  • 10. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
    Oncotarget; 2014 Sep 30; 5(18):8637-50. PubMed ID: 25226617
    [Abstract] [Full Text] [Related]

  • 11. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T.
    Leukemia; 2013 Jan 30; 27(1):118-29. PubMed ID: 22858987
    [Abstract] [Full Text] [Related]

  • 12. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P.
    Cancer Res; 2010 Feb 15; 70(4):1513-23. PubMed ID: 20145140
    [Abstract] [Full Text] [Related]

  • 13. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M, Ai H, Li T, Rajoria P, Shahu P, Li X.
    Biochem Biophys Res Commun; 2016 Apr 15; 472(4):610-6. PubMed ID: 26966074
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
    Blood; 2004 Oct 15; 104(8):2532-9. PubMed ID: 15256422
    [Abstract] [Full Text] [Related]

  • 15. Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions.
    Koldehoff M.
    Methods Mol Biol; 2015 Oct 15; 1218():277-92. PubMed ID: 25319658
    [Abstract] [Full Text] [Related]

  • 16. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P.
    Haematologica; 2017 Sep 15; 102(9):1519-1529. PubMed ID: 28596283
    [Abstract] [Full Text] [Related]

  • 17. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A, Buckle AM, Hiwarkar P, Syed F.
    PLoS One; 2015 Sep 15; 10(4):e0123016. PubMed ID: 25849484
    [Abstract] [Full Text] [Related]

  • 18. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
    Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, Bhatia R, Chen W.
    Blood; 2012 Feb 23; 119(8):1904-14. PubMed ID: 22207735
    [Abstract] [Full Text] [Related]

  • 19. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.
    Cancer Res; 2013 Sep 15; 73(18):5775-86. PubMed ID: 23887971
    [Abstract] [Full Text] [Related]

  • 20. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
    Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, O'Hare T, Deininger MW.
    Blood; 2015 Mar 12; 125(11):1772-81. PubMed ID: 25573989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.